Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G.M. D'Elia

Minimal Residual Disease (Mrd) in Early Stage Follicular Lymphoma Can Predict Prognosis and Drive Rituximab Treatment After Radiotherapy

Hematological Oncology

English

Related publications

Novel Molecular Markers for Minimal Residual Disease (Mrd) Monitoring in Mantle Cell and Follicular Lymphoma: The Targeted Locus Amplification (Tla) NGS Strategy

Hematological Oncology

English

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

British Journal of Haematology

Hematology

2018

English

Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)?

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2019

English

Monitoring of Minimal Residual Disease (MRD) Is Useful to Predict Prognosis of Adult Patients With Ph-Negative ALL: Results of a Prospective Study (ALL MRD2002 Study)

Journal of Hematology and Oncology

English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology

English

Preventing Relapse After Haematopoietic Stem Cell Transplantation for Acute Leukaemia: The Role of Post-Transplantation Minimal Residual Disease (MRD) Monitoring and MRD-directed Intervention

British Journal of Haematology

Hematology

2017

English

A Clofarabine-Based Bridging Regimen in Patients With Relapsed ALL and Persistent Minimal Residual Disease (MRD)

Bone Marrow Transplantation

Transplantation

Hematology

2013

English

Bone Marrow in Follicular Lymphoma Prognosis

Russian Journal of Biotherapy

2016

English

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G.M. D'Elia

Minimal Residual Disease (Mrd) in Early Stage Follicular Lymphoma Can Predict Prognosis and Drive Rituximab Treatment After Radiotherapy

Related publications

Novel Molecular Markers for Minimal Residual Disease (Mrd) Monitoring in Mantle Cell and Follicular Lymphoma: The Targeted Locus Amplification (Tla) NGS Strategy

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)?

Monitoring of Minimal Residual Disease (MRD) Is Useful to Predict Prognosis of Adult Patients With Ph-Negative ALL: Results of a Prospective Study (ALL MRD2002 Study)

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Preventing Relapse After Haematopoietic Stem Cell Transplantation for Acute Leukaemia: The Role of Post-Transplantation Minimal Residual Disease (MRD) Monitoring and MRD-directed Intervention

A Clofarabine-Based Bridging Regimen in Patients With Relapsed ALL and Persistent Minimal Residual Disease (MRD)

Bone Marrow in Follicular Lymphoma Prognosis

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY